Advancing Nuclear Medicine

Next week we will be attending the Total Body PET (TBPET) 2024 conference, the leading educational, scientific, research and networking event. The conference is expected to be attended by nuclear physicians, medical imaging specialists, (medical) physicists, scientists, clinicians, and industries with an interest in Total Body PET imaging. Visit our stand at the Forum in Groningen from 19-21 september. Let's meet! https://lnkd.in/eGaWfMeT

Do you want to receive our latest newsletter and stay up to date? Please go to our page: https://lnkd.in/gj85FESC

On Friday, 31 May, members of Control management of the Dutch Cancer Society visited NRG PALLAS at the Energy & Health Campus in Petten. NRG PALLAS provided an explanation of their contribution to the development of new nuclear medicines and the role of the new FIELD-LAB in this process. Read more: https://lnkd.in/eSGWMGXx

We are proud to announce that we installed our new Scientific Advisory Board (SAB) of NRG PALLAS at the Society of Nuclear Medicine and Molecular Imaging (SNMMI), last week in Toronto. Our SAB is chaired by Marnix Lam with members Erik Mittra, Niklaus Schaefer, Sandra Heskamp, Ghassan El-Haddad and Christophe Deroose. The SAB will provide expert guidance and advice on our projects within FIELD-LAB, and will ensure that our research, development, and strategic initiatives are grounded in robust scientific principles and methodologies. Key responsibilities include evaluating research proposals, advising on scientific trends and advancements. By offering an objective perspective, the SAB enhances the credibility and effectiveness of the organization's scientific endeavors, supporting innovation and informed decision-making. Overall, the SAB plays a crucial role in shaping the scientific direction and ensuring the integrity of the organisation's activities. #precisionmedicine #nuclearmedicine

On Friday, 31 May, the KWF Cancer Control management visited NRG PALLAS at the Energy & Health Campus in Petten. NRG PALLAS provided an explanation of their contribution to the development of new nuclear medicines and the role of the new FIELD-LAB in this process. Within FIELD-LAB, partners are collaborating on making medical isotopes available for clinical research to support new cancer treatments. From left to right: Patrick Ooms (KWF), Els Boter (KWF), Dorine Manson (KWF), Vinod Ramnandanlal (NRG PALLAS), Carla van Gils (KWF), Ronald Schram (NRG PALLAS), Karlijn van der Schilden (NRG PALLAS)

This week we will be attending the SNMMI Annual Meeting 2024 in Toronto. Want to meet up and talk about medical isotopes? https://lnkd.in/gUSrRHBz

NRGIPALLAS and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177). This will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. Read the full article: https://lnkd.in/grtbsyN6

On Wednesday, April 24th, the final discussion for one of the largest Kansen voor West II projects took place: FIELD-LAB. Representing Kansen voor West, Jeroen Elzenaar, Ruud van Raak en Tessa de Boer visited Petten to meet with Karlijn van der Schilden, Paula van der Vlies, Angelique de Boer-l'Istelle en Vinod Ramnandanlal. The Kansen voor West II project, named “Advancing Nuclear Medicine, Petten FIELD-LAB,” has resulted in a state-of-the-art GMP production facility. FIELD-LAB contributes to the acceleration of the development of new nuclear medicines. This facility is utilised for the production of promising radioactive materials for the preparation of innovative nuclear medications. FIELD-LAB also ensures the development of the necessary production processes. Significant achievements so far include a sustainable concept of a production system for two promising so-called starting materials and base material for two new therapies for cancer treatment. A tracer is being developed to better select patients for chemotherapy. Additionally, a dozen feasibility studies have been initiated for the product development of industrial parties. #precisionmedicine #healthcareinnovation #medicine #innovation

Last week, NRG|PALLAS (Yulia Buchatskaya and Fienke (J.A.M.) Nanne) attended the 21st European Symposium on Radiopharmacy & Radiopharmaceuticals (ESRR). The symposium showcased the current state of development of new Radiopharmaceuticals (nuclear medicine). We established many new connections and engaged in stimulating conversations. It is evident that this field of expertise is rapidly evolving and expanding. Consequently, there is growing interest and demand in products such as Pb-212 and Lu-177, both of which are under development at FIELD-LAB. #precisionmedicine #nuclearmedicine

In a significant achievement for the field of radionuclide production, a dedicated team consisting of scientists of NRG|PALLAS and Future Chemistry, has successfully completed the Site Acceptance Test (SAT) for their state-of-the-art, custom made Lu-177 no carrier added (n.c.a.) preparative High Performance Liquid Chromatography (prep-HPLC) system. Read the full article!